• EsoCap AG organized a multidisciplinary scientific advisory board meeting with eight international experts in Barrett’s esophagus (BE) in Zurich
• EsoCap’s technology for the topical treatment of Barrett’s esophagus was recognized by the experts for having high potential for clinical success
• EsoCap’s proprietary and unique targeted application technology for the upper gastrointestinal tract was shown to dramatically increase mucosal contact time. A Phase II clinical study is currently ongoing in eosinophilic esophagitis (EoE)

Read full PDF here